<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39320890</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2574-3805</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>03</Day></PubDate></JournalIssue><Title>JAMA network open</Title><ISOAbbreviation>JAMA Netw Open</ISOAbbreviation></Journal><ArticleTitle>Emerging SARS-CoV-2 Resistance After Antiviral Treatment.</ArticleTitle><Pagination><StartPage>e2435431</StartPage><MedlinePgn>e2435431</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2435431</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamanetworkopen.2024.35431</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="UNASSIGNED">Previous studies have identified mutations in SARS-CoV-2 strains that confer resistance to nirmatrelvir, yet how often this resistance arises and its association with posttreatment virologic rebound is not well understood.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To examine the prevalence of emergent antiviral resistance after nirmatrelvir treatment and its association with virologic rebound.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="UNASSIGNED">This cohort study enrolled outpatient adults with acute COVID-19 infection from May 2021 to October 2023. Participants were divided into those who received antiviral therapy and those who did not. The study was conducted at a multicenter health care system in Boston, Massachusetts.</AbstractText><AbstractText Label="EXPOSURE" NlmCategory="UNASSIGNED">Treatment regimen, including none, nirmatrelvir, and remdesivir.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="UNASSIGNED">The primary outcome was emergent SARS-CoV-2 antiviral resistance, defined as the detection of antiviral resistance mutations, which were not present at baseline, were previously associated with decreased antiviral efficacy, and emerged during or after completion of a participant's treatment. Next-generation sequencing was used to detect low frequency mutations down to 1% of the total viral population.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Overall, 156 participants (114 female [73.1%]; median [IQR] age, 56 [38-69] years) were included. Compared with 63 untreated individuals, the 79 who received nirmatrelvir were older and more commonly immunosuppressed. After sequencing viral RNA from participants' anterior nasal swabs, nirmatrelvir resistance mutations were detected in 9 individuals who received nirmatrelvir (11.4%) compared with 2 of those who did not (3.2%) (P = .09). Among the individuals treated with nirmatrelvir, those who were immunosuppressed had the highest frequency of resistance emergence (5 of 22 [22.7%]), significantly greater than untreated individuals (2 of 63 [3.1%]) (P = .01). Similar rates of nirmatrelvir resistance were found in those who had virologic rebound (3 of 23 [13.0%]) vs those who did not (6 of 56 [10.7%]) (P = .86). Most of these mutations (10 of 11 [90.9%]) were detected at low frequencies (&lt;20% of viral population) and reverted to the wild type at subsequent time points. Emerging remdesivir resistance mutations were only detected in immunosuppressed individuals (2 of 14 [14.3%]) but were similarly low frequency and transient. Global Initiative on Sharing All Influenza Data analysis showed no evidence of increased nirmatrelvir resistance in the United States after the authorization of nirmatrelvir.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="UNASSIGNED">In this cohort study of 156 participants, treatment-emergent nirmatrelvir resistance mutations were commonly detected, especially in individuals who were immunosuppressed. However, these mutations were generally present at low frequencies and were transient in nature, suggesting a low risk for the spread of nirmatrelvir resistance in the community with the current variants and drug usage patterns.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tamura</LastName><ForeName>Trevor J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choudhary</LastName><ForeName>Manish C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deo</LastName><ForeName>Rinki</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yousuf</LastName><ForeName>Fizah</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gomez</LastName><ForeName>Anadela Navarrete</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edelstein</LastName><ForeName>Gregory E</ForeName><Initials>GE</Initials><AffiliationInfo><Affiliation>Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boucau</LastName><ForeName>Julie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Ragon Institute of Massachusetts General Hospital, MIT and Harvard, Cambridge.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glover</LastName><ForeName>Owen T</ForeName><Initials>OT</Initials><AffiliationInfo><Affiliation>Ragon Institute of Massachusetts General Hospital, MIT and Harvard, Cambridge.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barry</LastName><ForeName>Mamadou</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gilbert</LastName><ForeName>Rebecca F</ForeName><Initials>RF</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reynolds</LastName><ForeName>Zahra</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yijia</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tien</LastName><ForeName>Dessie</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vyas</LastName><ForeName>Tammy D</ForeName><Initials>TD</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Passell</LastName><ForeName>Eliza</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Karry</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drapkin</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abar</LastName><ForeName>Emory G</ForeName><Initials>EG</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawano</LastName><ForeName>Yumeko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sparks</LastName><ForeName>Jeffrey A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wallace</LastName><ForeName>Zachary S</ForeName><Initials>ZS</Initials><AffiliationInfo><Affiliation>Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vyas</LastName><ForeName>Jatin M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Broad Institute, Cambridge, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shafer</LastName><ForeName>Robert W</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Stanford University School of Medicine, Palo Alto, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siedner</LastName><ForeName>Mark J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barczak</LastName><ForeName>Amy K</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ragon Institute of Massachusetts General Hospital, MIT and Harvard, Cambridge.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lemieux</LastName><ForeName>Jacob E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Broad Institute, Cambridge, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jonathan Z</ForeName><Initials>JZ</Initials><AffiliationInfo><Affiliation>Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>POSITIVES Study Team</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AI060354</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI176287</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AI110818</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Netw Open</MedlineTA><NlmUniqueID>101729235</NlmUniqueID><ISSNLinking>2574-3805</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>OF5P57N2ZX</RegistryNumber><NameOfSubstance UI="D000409">Alanine</NameOfSubstance></Chemical><Chemical><RegistryNumber>415SHH325A</RegistryNumber><NameOfSubstance UI="D000249">Adenosine Monophosphate</NameOfSubstance></Chemical><Chemical><RegistryNumber>3QKI37EEHE</RegistryNumber><NameOfSubstance UI="C000606551">remdesivir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>doi: 10.1001/jamanetworkopen.2024.35439</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="Y">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024882" MajorTopicYN="Y">Drug Resistance, Viral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000409" MajorTopicYN="Y">Alanine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000249" MajorTopicYN="Y">Adenosine Monophosphate</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Barry reported receiving grants from National Institutes of Health (NIH) during the conduct of the study. Ms Reynolds reported receiving grants from Massachusetts Consortium on Pathogen Readiness (MassCPR) and the NIH during the conduct of the study. Dr Y. Li reported serving as a topic editor for DynaMed outside the submitted work and being supported Rustbelt Center for AIDS Research. Ms Su reported receiving grants from the NIH during the conduct of the study. Mr Abar reported receiving grants from the NIH during the conduct of the study. Dr Sparks reported receiving grants from the NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases, the Gordon and Llura Gund Foundation, Boehringer Ingelheim, Bristol Myers Squibb, Sonoma Biosciences, and Janssen Pharmaceuticals as well as personal fees from AbbVie, Amgen, Gilead, Pfizer, ReCor, Sobi, and UCB outside the submitted work. Dr Wallace reported receiving grants from the NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases during the conduct of the study. Dr Shafer reported serving on the advisory board of and receiving speaking honorarium from Gilead Sciences and receiving speaking honorarium from ViiV Healthcare outside the submitted work. Dr Siedner reported receiving grants from the NIH and MassCPR during the conduct of the study. Dr Barczak reported serving as a consultant for ICON Government and Public Health Solutions outside the submitted work. Dr Lemieux reported receiving grants from MassCPR, the NIH, and the US Centers for Disease Control and Prevention during the conduct of the study as well as receiving grants from Moderna outside the submitted work. Dr J. Z. Li reported consulting for Abbvie and receiving grants from Merck during the conduct of the study. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>25</Day><Hour>22</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>25</Day><Hour>12</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>25</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39320890</ArticleId><ArticleId IdType="pmc">PMC11425144</ArticleId><ArticleId IdType="doi">10.1001/jamanetworkopen.2024.35431</ArticleId><ArticleId IdType="pii">2824050</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>US Food and Drug Administration. Fact sheet for healthcare providers: emergency use authorization for Paxlovid. Accessed August 21, 2024. https://www.fda.gov/media/155050/download</Citation></Reference><Reference><Citation>Hammond J, Leister-Tebbe H, Gardner A, et al. ; EPIC-HR Investigators . Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. N Engl J Med. 2022;386(15):1397-1408. doi:10.1056/NEJMoa2118542</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2118542</ArticleId><ArticleId IdType="pmc">PMC8908851</ArticleId><ArticleId IdType="pubmed">35172054</ArticleId></ArticleIdList></Reference><Reference><Citation>US Food and Drug Administration. Highlights of prescribing information: Veklury. Accessed August 21, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214787Orig1s000lbl.pdf</Citation></Reference><Reference><Citation>Iketani S, Mohri H, Culbertson B, et al. . Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir. Nature. 2023;613(7944):558-564. doi:10.1038/s41586-022-05514-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05514-2</ArticleId><ArticleId IdType="pmc">PMC9849135</ArticleId><ArticleId IdType="pubmed">36351451</ArticleId></ArticleIdList></Reference><Reference><Citation>Noske GD, de Souza Silva E, de Godoy MO, et al. . Structural basis of nirmatrelvir and ensitrelvir activity against naturally occurring polymorphisms of the SARS-CoV-2 main protease. J Biol Chem. 2023;299(3):103004. doi:10.1016/j.jbc.2023.103004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbc.2023.103004</ArticleId><ArticleId IdType="pmc">PMC9916189</ArticleId><ArticleId IdType="pubmed">36775130</ArticleId></ArticleIdList></Reference><Reference><Citation>Ullrich S, Ekanayake KB, Otting G, Nitsche C. Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir. Bioorg Med Chem Lett. 2022;62:128629. doi:10.1016/j.bmcl.2022.128629</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmcl.2022.128629</ArticleId><ArticleId IdType="pmc">PMC8856729</ArticleId><ArticleId IdType="pubmed">35182772</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang H, Zhou Y, Zou X, et al. . Evaluation of the inhibition potency of nirmatrelvir against main protease mutants of SARS-CoV-2 variants. Biochemistry. 2023;62(13):2055-2064. doi:10.1021/acs.biochem.3c00075</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.biochem.3c00075</ArticleId><ArticleId IdType="pubmed">37222536</ArticleId></ArticleIdList></Reference><Reference><Citation>Costacurta F, et al. . A comprehensive study of SARS-CoV-2 main protease (M(pro)) inhibitor-resistant mutants selected in a VSV-based system. bioRxiv. Preprint posted online October 4, 2023. doi:10.1101/2023.09.22.558628</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.09.22.558628</ArticleId><ArticleId IdType="pmc">PMC11407635</ArticleId><ArticleId IdType="pubmed">39259728</ArticleId></ArticleIdList></Reference><Reference><Citation>Greasley SE, Noell S, Plotnikova O, et al. . Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants. J Biol Chem. 2022;298(6):101972. doi:10.1016/j.jbc.2022.101972</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbc.2022.101972</ArticleId><ArticleId IdType="pmc">PMC9023115</ArticleId><ArticleId IdType="pubmed">35461811</ArticleId></ArticleIdList></Reference><Reference><Citation>Torii S, Kim KS, Koseki J, et al. ; Genotype to Phenotype Japan (G2P-Japan) Consortium . Increased flexibility of the SARS-CoV-2 RNA-binding site causes resistance to remdesivir. PLoS Pathog. 2023;19(3):e1011231. doi:10.1371/journal.ppat.1011231</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1011231</ArticleId><ArticleId IdType="pmc">PMC10089321</ArticleId><ArticleId IdType="pubmed">36972312</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens LJ, Pruijssers AJ, Lee HW, et al. . Mutations in the SARS-CoV-2 RNA-dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms. Sci Transl Med. 2022;14(656):eabo0718. doi:10.1126/scitranslmed.abo0718</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abo0718</ArticleId><ArticleId IdType="pmc">PMC9097878</ArticleId><ArticleId IdType="pubmed">35482820</ArticleId></ArticleIdList></Reference><Reference><Citation>Boucau J, Uddin R, Marino C, et al. . Characterization of virologic rebound following nirmatrelvir-ritonavir treatment for coronavirus disease 2019 (COVID-19). Clin Infect Dis. 2023;76(3):e526-e529. doi:10.1093/cid/ciac512</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac512</ArticleId><ArticleId IdType="pmc">PMC9384370</ArticleId><ArticleId IdType="pubmed">35737946</ArticleId></ArticleIdList></Reference><Reference><Citation>Edelstein GE, Boucau J, Uddin R, et al. . SARS-CoV-2 virologic rebound with nirmatrelvir-ritonavir therapy: an observational study. Ann Intern Med. 2023;176(12):1577-1585. doi:10.7326/M23-1756</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M23-1756</ArticleId><ArticleId IdType="pmc">PMC10644265</ArticleId><ArticleId IdType="pubmed">37956428</ArticleId></ArticleIdList></Reference><Reference><Citation>Charness ME, Gupta K, Stack G, et al. . Rebound of SARS-CoV-2 infection after nirmatrelvir-ritonavir treatment. N Engl J Med. 2022;387(11):1045-1047. doi:10.1056/NEJMc2206449</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2206449</ArticleId><ArticleId IdType="pmc">PMC9511633</ArticleId><ArticleId IdType="pubmed">36069968</ArticleId></ArticleIdList></Reference><Reference><Citation>Choudhary MC, Chew KW, Deo R, et al. ; ACTIV-2/A5401 Study Team . Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial. Nat Microbiol. 2022;7(11):1906-1917. doi:10.1038/s41564-022-01254-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-022-01254-1</ArticleId><ArticleId IdType="pmc">PMC9675946</ArticleId><ArticleId IdType="pubmed">36289399</ArticleId></ArticleIdList></Reference><Reference><Citation>Fajnzylber J, Regan J, Coxen K, et al. ; Massachusetts Consortium for Pathogen Readiness . SARS-CoV-2 viral load is associated with increased disease severity and mortality. Nat Commun. 2020;11(1):5493. doi:10.1038/s41467-020-19057-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-19057-5</ArticleId><ArticleId IdType="pmc">PMC7603483</ArticleId><ArticleId IdType="pubmed">33127906</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzou PL, Tao K, Pond SLK, Shafer RW. Coronavirus Resistance Database (CoV-RDB): SARS-CoV-2 susceptibility to monoclonal antibodies, convalescent plasma, and plasma from vaccinated persons. PLoS One. 2022;17(3):e0261045. doi:10.1371/journal.pone.0261045</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0261045</ArticleId><ArticleId IdType="pmc">PMC8906623</ArticleId><ArticleId IdType="pubmed">35263335</ArticleId></ArticleIdList></Reference><Reference><Citation>Github. FASTQ-to-CodFreq pipeline for HIV-1 and SARS-CoV-2. Accessed August 22, 2024. https://github.com/hivdb/codfreq</Citation></Reference><Reference><Citation>Li JZ, Stella N, Choudhary MC, et al. . Impact of pre-existing drug resistance on risk of virological failure in South Africa. J Antimicrob Chemother. 2021;76(6):1558-1563. doi:10.1093/jac/dkab062</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkab062</ArticleId><ArticleId IdType="pmc">PMC8599859</ArticleId><ArticleId IdType="pubmed">33693678</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanford University Coronavirus Antiviral &amp; Resistance Database. SARS-CoV-2 resistance mutations—3CLpro inhibitors. Accessed August 22, 2024. https://covdb.stanford.edu/drms/3clpro/</Citation></Reference><Reference><Citation>Stanford University Coronavirus Antiviral &amp; Resistance Database. SARS-CoV-2 resistance mutations—RdRP inhibitors. Accessed August 22, 2024. https://covdb.stanford.edu/drms/rdrp/</Citation></Reference><Reference><Citation>Khare S, Gurre C, Freitas L, et al. . GISAID’s role in pandemic response. China CDC Wkly. 2021;3(49):1049-1051. doi:10.46234/ccdcw2021.255</Citation><ArticleIdList><ArticleId IdType="doi">10.46234/ccdcw2021.255</ArticleId><ArticleId IdType="pmc">PMC8668406</ArticleId><ArticleId IdType="pubmed">34934514</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Choudhary MC, Regan J, et al. . SARS-CoV-2 viral clearance and evolution varies by type and severity of immunodeficiency. Sci Transl Med. 2024;16(731):eadk1599. doi:10.1126/scitranslmed.adk1599</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.adk1599</ArticleId><ArticleId IdType="pmc">PMC10982957</ArticleId><ArticleId IdType="pubmed">38266109</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuckerman NS, Bucris E, Keidar-Friedman D, Amsalem M, Brosh-Nissimov T. Nirmatrelvir resistance-de novo E166V/L50V mutations in an immunocompromised patient treated with prolonged nirmatrelvir/ritonavir monotherapy leading to clinical and virological treatment failure—a case report. Clin Infect Dis. 2024;78(2):352-355. doi:10.1093/cid/ciad494</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciad494</ArticleId><ArticleId IdType="pubmed">37596935</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirotsu Y, Kobayashi H, Kakizaki Y, et al. . Multidrug-resistant mutations to antiviral and antibody therapy in an immunocompromised patient infected with SARS-CoV-2. Med. 2023;4(11):813-824.e4. doi:10.1016/j.medj.2023.08.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medj.2023.08.001</ArticleId><ArticleId IdType="pubmed">37683636</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenke K, Lewis MC, Feldmann F, et al. . Combined molnupiravir-nirmatrelvir treatment improves the inhibitory effect on SARS-CoV-2 in macaques. JCI Insight. 2023;8(4):e166485. doi:10.1172/jci.insight.166485</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.166485</ArticleId><ArticleId IdType="pmc">PMC9977490</ArticleId><ArticleId IdType="pubmed">36574296</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Gammeltoft KA, Ryberg LA, et al. . Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system. Sci Adv. 2022;8(51):eadd7197. doi:10.1126/sciadv.add7197</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.add7197</ArticleId><ArticleId IdType="pmc">PMC9770952</ArticleId><ArticleId IdType="pubmed">36542720</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith-Jeffcoat SE, et al. . Symptoms, viral loads, and rebound among COVID-19 outpatients treated with nirmatrelvir/ritonavir compared to propensity score-matched untreated individuals. Clin Infect Dis. 2024;78(5):1175-1184. doi:10.1093/cid/ciad696</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciad696</ArticleId><ArticleId IdType="pmc">PMC11090981</ArticleId><ArticleId IdType="pubmed">37963102</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo W, He D, Liang C, et al. . The persistence of SARS-CoV-2 in tissues and its association with long COVID symptoms: a cross-sectional cohort study in China. Lancet Infect Dis. 2024;24(8):845-855. doi:10.1016/S1473-3099(24)00171-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(24)00171-3</ArticleId><ArticleId IdType="pubmed">38663423</ArticleId></ArticleIdList></Reference><Reference><Citation>Huot N, Planchais C, Rosenbaum P, et al. . SARS-CoV-2 viral persistence in lung alveolar macrophages is controlled by IFN-γ and NK cells. Nat Immunol. 2023;24(12):2068-2079. doi:10.1038/s41590-023-01661-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-023-01661-4</ArticleId><ArticleId IdType="pmc">PMC10681903</ArticleId><ArticleId IdType="pubmed">37919524</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal AD, VanElzakker MB, Aleman S, et al. . SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC). Nat Immunol. 2023;24(10):1616-1627. doi:10.1038/s41590-023-01601-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-023-01601-2</ArticleId><ArticleId IdType="pubmed">37667052</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>